著者

Masaomi Nangaku Takashi Kadowaki Hiroshi Yotsuyanagi Norio Ohmagari Moritoki Egi Junichi Sasaki Tetsuya Sakamoto Yoshinori Hasegawa Takashi Ogura Shigeru Chiba Koichi Node Ryo Suzuki Yasuhiro Yamaguchi Atsuko Murashima Norihiko Ikeda Eriko Morishita Kenji Yuzawa Hiroyuki Moriuchi Satoshi Hayakawa Daisuke Nishi Atsushi Irisawa Toshiaki Miyamoto Hidetaka Suzuki Hirohito Sone Yuuji Fujino

出版者

Japan Medical Association / The Japanese Associaiton of Medical Sciences

雑誌

JMA Journal (ISSN:2433328X)

巻号頁・発行日

vol.4, no.2, pp.148-162, 2021-04-15 (Released:2021-05-07)

参考文献数

69

被引用文献数

7

---

In 2020, the COVID-19 pandemic has had unprecedented impacts on various aspects of the world. Each academic society has published a guide and/or guidelines on how to cope with COVID-19 separately. As the one and only nationwide association of academic societies that represent medical science in Japan, JMSF has decided to publish the expert opinion to help patients and care providers find specifically what they want.This expert opinion is a summary of recommendations by many academic societies and will be updated when necessary. Patients that each academic society targets differ even though they suffer from the same COVID-19, and recommendations can be different in a context-dependent manner. Readers are supposed to be flexible and adjustable when they use this expert opinion.

著者

Hisanori Horiuchi Eriko Morishita Tetsumei Urano Kenji Yokoyama the Questionnaire-survey Joint Team on The COVID-19-related thrombosis

出版者

Japan Atherosclerosis Society

雑誌

Journal of Atherosclerosis and Thrombosis (ISSN:13403478)

巻号頁・発行日

vol.28, no.4, pp.406-416, 2021-04-01 (Released:2021-04-01)

参考文献数

15

被引用文献数

45

---

A questionnaire on COVID-19-related thrombosis in patients hospitalized before Aug 31, 2020, was sent to 399 hospitals throughout Japan. Responses were received from 111 (27.8%) with information on 6,202 COVID-19 patients. Of these, 333 and 56 required ventilation or extracorporeal membrane oxygenation (ECMO), respectively, and 212 died (3.4%). D-dimer levels were measured in 75.0% of the patients, revealing that 9.2% and 7.6% exhibited D-dimer increases of 3-8-fold and ≥8-fold the reference value, respectively. Thrombotic events occurred in 108 patients (1.86% of the 5,807 patients with available data) including symptomatic cerebral infarction in 24, myocardial infarction in 7, deep vein thrombosis in 41, pulmonary thromboembolism in 30, and other thrombotic events in 22. Some patients developed multiple thrombotic events. Thrombosis occurred in 32 patients with mild or moderate COVID-19 severity (0.59% of those with data available) and in 52 patients on ventilation or ECMO (13.5% of severe patients for whom data were available). Thrombosis occurred in 67 patients during worsening clinical condition and in 26 during recovery. Anticoagulant therapy was provided to 893 patients (14.6% of the 6,119 patients with available data), the main reasons being provided as elevated D-dimer levels and worsening clinical condition.